

## RESEARCH

### BOB Economics Research | FY21 Budget Preview

Investment revival a priority

### ICICI Bank | Target: Rs 625 | +17% | BUY

Core profitability remains strong

### Supreme Industries | Target: Rs 1,385 | +5% | ADD

Margins surprise positively, volumes disappoint

## SUMMARY

### India Economics: FY21 Budget Preview

We believe reviving growth and investments will take centre stage in FY21 Budget. The government has been undertaking structural reforms to encourage investments. While government and foreign investments have increased, private sector NPA cycle has been holding back private investments. We believe private sector investments can be started with asset monetisation program which will give room to government to spend on infra assets and restrict fiscal deficit to 3.6% and 3.3% of GDP in FY20 and FY21.

[Click here for the full report.](#)

### ICICI Bank

ICICI Bank's (ICICIBC) Q3FY20 PAT at Rs 41bn was driven by 24% YoY growth in NII and lower provisions. Slippages increased to Rs 44bn due to two corporate accounts, while the retail business saw higher slippages from the Kisan credit card and CV portfolios. However, GNPA ratio declined to 6% given recoveries from Essar Steel resolution. The bank's BB-&-below pool increased to Rs 174bn (2.7% of loans) led by downgrades in the telecom sector. We broadly maintain estimates and roll over to a revised Mar'21 TP of Rs 625 (vs. Rs 525).

[Click here for the full report.](#)

## TOP PICKS

### LARGE-CAP IDEAS

| Company                             | Rating | Target |
|-------------------------------------|--------|--------|
| <a href="#">Cipla</a>               | Buy    | 570    |
| <a href="#">Eicher Motors</a>       | Buy    | 25,000 |
| <a href="#">Petronet LNG</a>        | Buy    | 400    |
| <a href="#">Reliance Industries</a> | Buy    | 1,860  |
| <a href="#">TCS</a>                 | Add    | 2,390  |

### MID-CAP IDEAS

| Company                             | Rating | Target |
|-------------------------------------|--------|--------|
| <a href="#">Alkem Labs</a>          | Buy    | 2,290  |
| <a href="#">Future Supply</a>       | Buy    | 680    |
| <a href="#">Greenply Industries</a> | Buy    | 210    |
| <a href="#">Laurus Labs</a>         | Buy    | 480    |
| <a href="#">Ashok Leyland</a>       | Sell   | 68     |

Source: BOBCAPS Research

### DAILY MACRO INDICATORS

| Indicator              | Current | 2D (%)    | 1M (%)    | 12M (%) |
|------------------------|---------|-----------|-----------|---------|
| US 10Y yield (%)       | 1.73    | (4bps)    | (20bps)   | (98bps) |
| India 10Y yield (%)    | 6.60    | (4bps)    | 3bps      | (71bps) |
| USD/INR                | 71.27   | (0.1)     | (0.1)     | (0.3)   |
| Brent Crude (US\$/bbl) | 62.04   | (1.9)     | (6.6)     | 1.6     |
| Dow                    | 29,160  | (0.1)     | 2.1       | 18.8    |
| Shanghai               | 2,977   | (2.8)     | 0.5       | 14.8    |
| Sensex                 | 41,386  | 0.7       | (0.6)     | 14.3    |
| India FII (US\$ mn)    | 22 Jan  | MTD       | CYTD      | FYTD    |
| FII-D                  | 130.2   | (1,591.4) | (1,591.4) | 1,352.7 |
| FII-E                  | 4.0     | 1,940.4   | 1,940.4   | 9,329.6 |

Source: Bank of Baroda Economics Research

### BOBCAPS Research

research@bobcaps.in



## Supreme Industries

Supreme Industries (SI) reported below-estimated Q3FY20 revenue (-2.6% YoY) owing to flat volumes. EBITDA margins beat estimates, expanding 360bps YoY to 16.1% YoY on the back of lower RM cost (-430bps) – this aided healthy EBITDA/PBT growth of 26%/24% YoY. Management has maintained guidance of 10-12% volume growth in FY20 but increased operating margin guidance from 13-14% to 14-14.5%. We raise FY20-FY22 earnings estimates by 2-4% and roll to a Mar'21 TP of Rs 1,385 (earlier Rs 1,235).

[Click here](#) for the full report.

## FY21 BUDGET PREVIEW

24 January 2020

### Investment revival a priority

**We believe reviving growth and investments will take centre stage in FY21 Budget. The government has been undertaking structural reforms to encourage investments. While government and foreign investments have increased, private sector NPA cycle has been holding back private investments. We believe private sector investments can be started with asset monetisation program which will give room to government to spend on infra assets and restrict fiscal deficit to 3.6% and 3.3% of GDP in FY20 and FY21.**

Sameer Narang

Sonal Badhan | Dipanwita Mazumdar

Aditi Gupta | Jahnavi

chief.economist@bankofbaroda.com

**FY20 fiscal deficit at 3.6%:** Given the backdrop of a slowing economy and muted revenue growth along with reduction in corporate tax rate to boost investments, the Centre is expected to report fiscal deficit of 3.6% (BE: 3.3%). Out of the 0.3% expansion, 10bps is owing to lower nominal GDP growth. The remaining is on account of lower revenue collections. We believe this slippage can be managed by increase in inflows from short-term borrowing and National Small Savings Fund (NSSF).

**Investment revival a priority:** Investment demand is estimated to have increased at 1% in FY20 (10% in FY19). Even consumption has slowed down to 5.8% in FY20 (8.1% in FY19). Thus reviving investment takes a priority. The government has taken a number of steps to improve India's Ease of Doing Business rankings. Corporate tax rate is now globally competitive. The government has also laid out an infra pipeline which aims to double investments in the next five years. The resources to fund infra investments can come from asset monetisation. It will also boost private sector capex and credit off-take to takeover these assets. Real estate sector can be given a boost through tax incentive to buy a house.

**FY21 fiscal deficit at 3.3% of GDP:** We expect direct and indirect tax revenues to increase by 10.1% and 7% in FY21 respectively. Non-tax revenues should increase on account of AGR and 5G auction receipts from telecom sector. On the expenditure front, capital spending is likely to increase by 8.5%. Focus will be on roads and railways. EBR spending will also accelerate in-line with infra pipeline. On the revenue expenditure front, PM-KISAN will see higher allocation. This translates to fiscal deficit of Rs 7.4tn or 3.3% of GDP in FY21, implying gross and net borrowing of Rs 8.2tn (Rs 7.1tn in FY20) and Rs 5.1tn (Rs 4.7tn in FY20) respectively.

#### KEY HIGHLIGHTS

- Agriculture, infrastructure and asset monetisation to be key focus areas of FY21 Budget
- Fiscal deficit for FY20/FY21 estimated at 3.6%/3.3% of GDP
- Gross/net borrowings in FY21 estimated at Rs 8.2tn/Rs 5.1tn



**BUY**

TP: Rs 625 | ▲ 17%

**ICICI BANK**

Banking

25 January 2020

## Core profitability remains strong

ICICI Bank's (ICICIBC) Q3FY20 PAT at Rs 41bn was driven by 24% YoY growth in NII and lower provisions. Slippages increased to Rs 44bn due to two corporate accounts, while the retail business saw higher slippages from the Kisan credit card and CV portfolios. However, GNPA ratio declined to 6% given recoveries from Essar Steel resolution. The bank's BB-&-below pool increased to Rs 174bn (2.7% of loans) led by downgrades in the telecom sector. We broadly maintain estimates and roll over to a revised Mar'21 TP of Rs 625 (vs. Rs 525).

Vikesh Mehta

research@bobcaps.in

**Recoveries aid lower GNPA:** Slippages increased to Rs 44bn in Q3 (vs. Rs 25bn in Q2) as two corporate accounts – one broking sector (100% provided) and one industrial – slipped into NPA. Retail slippages were higher due to the Kisan credit card (KCC) and CV portfolios. However, the bank's GNPA ratio declined 40bps QoQ to 6% on recoveries from Essar Steel.

The BB-&-below rated pool increased to Rs 174bn (2.7% of loans) vs. Rs 161bn (2.6%) in Q2, given downgrades worth Rs 27bn across sectors (largely telecom). Asset quality divergence from RBI's audit for FY19 was below threshold levels. Barring the KCC and CV segments, risks in most retail segments including unsecured personal loans and credit cards are within acceptable limits for the bank.

**Loan growth stable; NIMs increase:** Loan growth at ~13% YoY was largely aided by 19% growth in retail while the SME book (~3% of loans) grew 34%. The bank's overseas portfolio declined 16% YoY and now forms ~9% of loans. NIM increased to 3.77% (3.64% in Q2) and included a 10bps (6bps in Q2) impact from interest reversals.

**Maintain BUY:** We believe ICICIBC is well placed to play the turning asset quality cycle. Maintain BUY with a revised TP of Rs 625 on rollover.

|                  |                   |
|------------------|-------------------|
| Ticker/Price     | ICICIBC IN/Rs 534 |
| Market cap       | US\$ 48.3bn       |
| Shares o/s       | 6,453mn           |
| 3M ADV           | US\$ 166.0mn      |
| 52wk high/low    | Rs 552/Rs 336     |
| Promoter/FPI/DII | 0%/45%/55%        |

Source: NSE

## STOCK PERFORMANCE



Source: NSE

## KEY FINANCIALS

| Y/E 31 Mar              | FY18A   | FY19A   | FY20E   | FY21E   | FY22E   |
|-------------------------|---------|---------|---------|---------|---------|
| Net interest income     | 230,258 | 270,148 | 325,724 | 379,336 | 449,521 |
| NII growth (%)          | 5.9     | 17.3    | 20.6    | 16.5    | 18.5    |
| Adj. net profit (Rs mn) | 67,774  | 33,633  | 119,137 | 204,931 | 255,922 |
| EPS (Rs)                | 11.1    | 5.2     | 18.5    | 31.8    | 39.7    |
| P/E (x)                 | 48.3    | 102.2   | 28.9    | 16.8    | 13.4    |
| P/BV (x)                | 3.3     | 3.2     | 3.0     | 2.6     | 2.3     |
| ROA (%)                 | 0.8     | 0.4     | 1.2     | 1.7     | 1.9     |
| ROE (%)                 | 6.6     | 3.2     | 10.7    | 16.8    | 18.3    |

Source: Company, BOBCAPS Research



**ADD**

TP: Rs 1,385 | ▲ 5%

**SUPREME INDUSTRIES**

Plastic Products

24 January 2020

## Margins surprise positively, volumes disappoint

**Supreme Industries (SI) reported below-estimated Q3FY20 revenue (-2.6% YoY) owing to flat volumes. EBITDA margins beat estimates, expanding 360bps YoY to 16.1% YoY on the back of lower RM cost (-430bps) – this aided healthy EBITDA/PBT growth of 26%/24% YoY. Management has maintained guidance of 10-12% volume growth in FY20 but increased operating margin guidance from 13-14% to 14-14.5%. We raise FY20-FY22 earnings estimates by 2-4% and roll to a Mar'21 TP of Rs 1,385 (earlier Rs 1,235).**

Arun Baid

research@bobcaps.in

**Volumes flat:** SI's Q3 revenues dipped 2.6% YoY to Rs 13.7bn with blended volume growth of 0.4%. Value growth was lower than volume growth due to a decline in raw material prices, resulting in lower realisations. During the quarter, plastic piping volumes were flat YoY while packaging and consumer products increased 4.7% and 6.6% respectively; industrial products declined 11%. As per management, demand was slow in the first half of Q3 due to the festival period and extended rains, but revived in the second half. Volume growth guidance has been maintained at 10-12% for FY20 (up ~8.5% YoY in 9MFY20).

**Lower RM cost aids margins:** SI's operating margins expanded 360bps YoY to 16.1% due to lower raw material cost (+427bps) and higher value-added product sales (41.5% revenue share vs. 37.7% YoY), which comfortably offset higher employee expenses (+53bps). EBITDA/PBT grew 26%/24% YoY. Management has increased FY20 margin guidance to 14-14.5% (vs. 13-14%).

**Maintain ADD:** We raise FY20-FY22 earnings estimates by 2-4% to build in the Q3 beat and move to a revised Mar'21 TP of Rs 1,385 (earlier Rs 1,235). Maintain ADD as we continue to like SI for its strong brand, comprehensive portfolio and sound balance sheet.

|                  |                 |
|------------------|-----------------|
| Ticker/Price     | SI IN/Rs 1,321  |
| Market cap       | US\$ 2.4bn      |
| Shares o/s       | 127mn           |
| 3M ADV           | US\$ 0.8mn      |
| 52wk high/low    | Rs 1,350/Rs 946 |
| Promoter/FPI/DII | 50%/8%/42%      |

Source: NSE

## STOCK PERFORMANCE



Source: NSE

## KEY FINANCIALS

| Y/E 31 Mar              | FY18A  | FY19A  | FY20E  | FY21E  | FY22E  |
|-------------------------|--------|--------|--------|--------|--------|
| Total revenue (Rs mn)   | 49,633 | 56,086 | 58,192 | 65,583 | 74,071 |
| EBITDA (Rs mn)          | 7,841  | 7,812  | 8,129  | 9,365  | 10,662 |
| Adj. net profit (Rs mn) | 4,242  | 3,683  | 4,731  | 5,574  | 6,473  |
| Adj. EPS (Rs)           | 33.4   | 29.0   | 37.2   | 43.9   | 51.0   |
| Adj. EPS growth (%)     | 0.1    | (13.2) | 28.5   | 17.8   | 16.1   |
| Adj. ROAE (%)           | 23.6   | 18.2   | 20.8   | 21.9   | 22.7   |
| Adj. P/E (x)            | 39.6   | 45.6   | 35.5   | 30.1   | 25.9   |
| EV/EBITDA (x)           | 21.0   | 21.2   | 20.4   | 17.8   | 15.7   |

Source: Company, BOBCAPS Research



## Disclaimer

### Recommendations and Absolute returns (%) over 12 months

**BUY** – Expected return >+15%

**ADD** – Expected return from >+5% to +15%

**REDUCE** – Expected return from -5% to +5%

**SELL** – Expected return <-5%

**Note:** Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

### Rating distribution

As of 31 December 2019, out of 83 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 50 have BUY ratings, 18 are rated ADD, 9 are rated REDUCE and 6 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

### Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

### Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

### General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS’s prior written consent.

#### **Other disclosures**

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS’s associates may have financial interest in the subject company. BOBCAPS’s associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.